Stockscreener 앱 받기
40.51
2.90%
1.14
시간 외 거래:
40.62
0.11
+0.27%
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
IDYA Maintains Outperform Rating by RBC Capital -- Price Target Lowered to $48 - GuruFocus
Ideaya Biosciences stock hits 52-week high at $39.28 By Investing.com - Investing.com South Africa
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion - simplywall.st
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2500 Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to EBITDA forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Price to book forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to book forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to sales forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Price to earnings forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
IDEAYA Biosciences, Inc. Actuals & Estimates (SWB:30J) - TradingView
30J Forecast — Price Target — Prediction for 2027 - TradingView
(IDYA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
IDEAYA Biosciences, Inc. Actuals & Estimates (DUS:30J) - TradingView
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
IDEAYA Biosciences, Inc. Actuals & Estimates (NASDAQ:IDYA) - TradingView
IDEAYA lures 4 new hires with 98,000 stock options - Stock Titan
IDYA Forecast — Price Target — Prediction for 2027 - TradingView
IDEAYA Biosciences Shareholders Back Leadership, Governance Changes - TipRanks
Shareholders back IDEAYA (NASDAQ: IDYA) proposals as board names new chair - Stock Titan
IDEAYA Biosciences Inc (IDYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Director at IDEAYA Biosciences (IDYA) receives 20,000-share stock option grant - Stock Titan
IDEAYA Biosciences (IDYA) director receives stock options on 20,000 shares - Stock Titan
IDEAYA (IDYA) director receives grant of 20,000 stock options - Stock Titan
IDEAYA (IDYA) director Terry Rosen receives 20,000 stock options at $30.57 - Stock Titan
IDEAYA (IDYA) director Scott Morrison receives grant of 20,000 stock options - Stock Titan
IDEAYA Biosciences (IDYA) director awarded stock options on 20,000 shares - Stock Titan
IDEAYA Biosciences Inc (IDYA) Institutional Confidence - TradingKey
IDEAYA Biosciences Inc (IDYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IDEAYA Biosciences Inc (IDYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IDEAYA Biosciences Inc (IDYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
IDEAYA Biosciences Inc (IDYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IDEAYA Biosciences elects Yujiro S. Hata board chairman - grafa.com
IDEAYA Biosciences, Inc. Announces Yujiro S. Hata Elected as Chairman of Board of Directors - marketscreener.com
IDEAYA Biosciences Elects CEO Yujiro Hata as Chairman - marketscreener.com
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors - Barchart.com
IDEAYA Biosciences Inc (IDYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IDEAYA Biosciences Inc (IDYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
IDEAYA Biosciences (IDYA) Surges 4.31%: Breaking Through Resistance Levels?Earnings Beat Stocks - newsline.com
Responsive Playbooks and the IDYA Inflection - Stock Traders Daily
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class M - GuruFocus
Ideaya Biosciences stock rises on phase 1/2 cancer trial start By Investing.com - Investing.com South Africa
IDEAYA Biosciences enrolls first patient in IDE892 Phase 1/2 trial - grafa.com
Why is Ideaya Biosciences stock rallying today? By Investing.com - Investing.com Canada
Ideaya Biosciences stock rises on phase 1/2 cancer trial start - Investing.com Nigeria
Ideaya begins trial of IDE892 combo in lung, pancreatic cancer - Investing.com
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
New drug combo targets MTAP-deleted pancreatic and lung cancers - Stock Titan
Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
IDEAYA Biosciences, Inc. (IDYA) reports Q1 loss, misses revenue estimates - MSN
1.17%
2.48%
자본화:
|
볼륨(24시간):